MedTrace Logo

A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

NCT04575311 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-05-24

No results posted yet for this study

Summary

A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

AB680

AB680 is a Cluster of Differentiation (CD)73 Inhibitor

OTHER

Placebo

Matching Placebo

Sponsors & Collaborators

  • Arcus Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-20
Primary Completion
2021-09-22
Completion
2021-09-22

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04575311 on ClinicalTrials.gov